Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CXCR5 | P32302 | 5/20 | 0.32 |
| ▸ | BCL2 | P10415 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | PGK1 | P00558 | 1/20 | 0.32 |
| ▸ | PGK2 | P07205 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | DBH | P09172 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15698070 | 0.79 | FFAR1 (0.38) | POLBFFAR1BCL2MCL1KDM4E | |
| SCHEMBL18878381 | 0.78 | KDM4E (0.40) | POLBL3MBTL1FFAR1BCL2MCL1 | |
| SCHEMBL18878382 | 0.76 | NPSR1 (0.37) | POLBL3MBTL1FFAR1ALOX15ALOX12 | |
| SCHEMBL18878385 | 0.73 | GABRA1 (0.38) | POLBL3MBTL1ALDH1A1 | |
| SCHEMBL18878378 | 0.71 | LMNA (0.39) | POLBL3MBTL1FFAR1GAAALDH1A1 | |
| SCHEMBL9875150 | 0.70 | AKR1C2 (0.38) | POLBL3MBTL1KDM4EGAAALDH1A1 | |
| SCHEMBL18878383 | 0.70 | GABRA1 (0.47) | — | |
| SCHEMBL26177667 | 0.70 | POLB (0.46) | POLBFFAR1BCL2MCL1KDM4E | |
| SCHEMBL3350799 | 0.69 | POLB (0.47) | POLBL3MBTL1CXCR5ALDH1A1 | |
| SCHEMBL18878377 | 0.68 | FFAR1 (0.40) | POLBL3MBTL1FFAR1KDM4EDBH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951074-B2 | Dihydropteridinone derivatives and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145013-A1 | DIHYDROPTERIDINONE DERIVATIVES AND USES THEREOF | BRDT, BRD4, BRD3 | POLB 183/4885L3MBTL1 3597/4885FFAR1 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.